Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
Hana M El SahlyLindsey R BadenBrandon EssinkSusanne Doblecki-LewisJudith M MartinLarry J AndersonThomas B CampbellJesse L ClarkLisa A JacksonCarl J FichtenbaumMarcus ZervosBruce RankinFrank EderGregory FeldmanChristina KennellyLaurie Han-ConradMichael LevinKathleen M NeuzilLawrence CoreyPeter GilbertHolly JanesDean FollmannMary MarovichLaura PolakowskiJohn R MascolaJulie E LedgerwoodBarney S GrahamAllison AugustHeather CloutingWeiping DengShu HanBrett LeavDeb ManzoRolando PajonFlorian SchödelJoanne E TomassiniHonghong ZhouJacqueline Millernull nullPublished in: The New England journal of medicine (2021)
The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).